EWI-F, also known as PTGFRN, is inversely related to the loss of CD9. Its expression correlates with the metastatic status of hLT. EWI-F inhibits the binding of prostaglandin F2-alpha (PGF2-alpha) to its specific FP receptor, by decreasing the receptor number rather than the affinity constant. EWI-F expression positively correlates with the metastatic status of hLT, and that the upregulation of EWI-F expression could be one of the mechanisms underlying the loss of CD9 in solid tumours.
TMPY-03876
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
